AR034320A1 - Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo - Google Patents

Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo

Info

Publication number
AR034320A1
AR034320A1 ARP020101580A ARP020101580A AR034320A1 AR 034320 A1 AR034320 A1 AR 034320A1 AR P020101580 A ARP020101580 A AR P020101580A AR P020101580 A ARP020101580 A AR P020101580A AR 034320 A1 AR034320 A1 AR 034320A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical dosage
dosage form
amorfo
mesilate
nelfinavir
Prior art date
Application number
ARP020101580A
Other languages
English (en)
Inventor
Martin Howard Infeld
Navnit Hargovindas Shah
Lin Zhang
Wantanee Phuapradit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR034320A1 publication Critical patent/AR034320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una forma de dosificación farmacéutica oral unitaria sólida de mesilato de nelfinavir amorfo que comprende mesilato de nelfinavir amorfo, y un polímero sintético, no iónico, de bloqueo de óxido de etileno y óxido de propileno, soluble en agua, farmacéuticamente aceptable, teniendo dicho copolímero un punto de fusión de al menos 40°C. Se proporciona un proceso de granulación de fusión caliente para la elaboración de una forma de dosificación. Forma de dosificación oral unitaria sólida para uso en terapia, particularmente para el tratamiento de enfermedades mediadas por HIV.
ARP020101580A 2001-05-03 2002-04-30 Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo AR034320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03

Publications (1)

Publication Number Publication Date
AR034320A1 true AR034320A1 (es) 2004-02-18

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101580A AR034320A1 (es) 2001-05-03 2002-04-30 Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo

Country Status (36)

Country Link
US (1) US7014866B2 (es)
EP (1) EP1390063B1 (es)
JP (1) JP4101661B2 (es)
KR (1) KR100554816B1 (es)
CN (1) CN1255185C (es)
AR (1) AR034320A1 (es)
AT (1) ATE282428T1 (es)
BG (1) BG108311A (es)
BR (1) BR0209325A (es)
CA (1) CA2444116C (es)
CZ (1) CZ20033211A3 (es)
DE (1) DE60201988T2 (es)
EA (1) EA006627B1 (es)
EC (1) ECSP034827A (es)
ES (1) ES2231717T3 (es)
GE (1) GEP20053466B (es)
GT (1) GT200200079A (es)
HR (1) HRP20030873B1 (es)
HU (1) HU229938B1 (es)
IL (2) IL158306A0 (es)
IS (1) IS7010A (es)
JO (1) JO2401B1 (es)
MA (1) MA27018A1 (es)
MX (1) MXPA03009971A (es)
MY (1) MY128509A (es)
NO (1) NO20034689L (es)
NZ (1) NZ528689A (es)
PA (1) PA8544501A1 (es)
PE (1) PE20021159A1 (es)
PL (1) PL366998A1 (es)
PT (1) PT1390063E (es)
RS (1) RS83503A (es)
SK (1) SK14572003A3 (es)
TW (1) TWI234461B (es)
UA (1) UA76463C2 (es)
WO (1) WO2002089835A2 (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
CN100475209C (zh) 2003-07-15 2009-04-08 阿利健制药有限公司 抗冠状病毒剂
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
WO2006060711A2 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
CA2623237C (en) 2005-09-23 2013-07-09 F. Hoffmann-La Roche Ag Novel dosage formulation
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
PT2054040E (pt) * 2006-08-16 2011-06-30 Novartis Ag Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
CA2686545C (en) * 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP2527336A1 (en) 2007-04-25 2012-11-28 Concert Pharmaceuticals Inc. Deuterated analogues of cilostazol
CA2630084A1 (en) * 2007-04-30 2008-10-30 Mark Andreychuk Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
EP2345653B1 (en) * 2007-05-01 2012-12-26 Concert Pharmaceuticals Inc. Morphinan compounds
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
EP3093290B1 (en) 2007-05-01 2018-01-24 Concert Pharmaceuticals Inc. Morphinan compounds
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
BRPI0816513A2 (pt) * 2007-10-19 2015-03-24 Purdue Research Foundation Composição farmacêutica e método para preparar a suspensão sólida
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
MX2010009300A (es) 2008-02-29 2010-11-05 Concert Pharmaceuticals Inc Derivados de xantina substituidos.
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
EP2334678B1 (en) 2008-09-19 2012-12-26 Concert Pharmaceuticals Inc. Morphinan compounds
EP2364151A1 (en) 2008-10-30 2011-09-14 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
WO2010062692A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
CA2800442C (en) * 2010-06-14 2018-05-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
SI3235812T1 (sl) 2011-05-18 2020-02-28 Vertex Pharmaceuticals (Europe) Limited Devterirani derivati ivakaftorja
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP2015512947A (ja) 2012-04-13 2015-04-30 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
PT3882249T (pt) 2012-06-15 2025-08-06 Sun Pharmaceutical Ind Inc Derivados deuterados de ruxolitinib
WO2014012009A1 (en) 2012-07-12 2014-01-16 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP3492472A1 (en) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
EP2935251A1 (en) 2012-12-20 2015-10-28 Concert Pharmaceuticals Inc. Deuterated alk inhibitors
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
US20160024084A1 (en) 2013-03-15 2016-01-28 Concert Pharmaceuticals, Inc. Deuterated palbociclib
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
KR102509043B1 (ko) 2014-06-06 2023-03-09 리써치 트라이앵글 인스티튜트 아펠린 수용체(apj) 효능제 및 이의 용도
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
US10301281B2 (en) 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
HK1258472A1 (zh) 2015-09-21 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftr增效剂的施用
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
EP4424367A3 (en) 2016-05-04 2024-11-13 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
EP4122919A1 (en) 2016-07-04 2023-01-25 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
KR102511953B1 (ko) 2016-08-01 2023-03-20 더 브리검 앤드 우먼즈 하스피털, 인크. 단백질 및 펩티드 전달용 입자
EP3558996A4 (en) 2016-12-21 2020-08-05 Research Triangle Institute, International DIARYLPURINE DERIVATIVES WITH ENHANCED BIOAVAILABILITY
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
PH12019502544B1 (en) 2017-05-19 2023-07-26 Superb Wisdom Ltd Derivatives of resiquimod
US20200368193A1 (en) 2017-11-22 2020-11-26 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
US12465605B2 (en) 2019-04-10 2025-11-11 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
KR20230093504A (ko) 2020-10-28 2023-06-27 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 억제제를 이용한 탈모 장애의 치료를 위한 요법
CA3228505A1 (en) 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN119255806A (zh) 2022-05-04 2025-01-03 太阳医药工业公司 用于用氘化jak抑制剂进行治疗的剂量方案

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
EP1028712B1 (en) * 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
DK1227797T3 (da) * 1999-11-12 2005-05-30 Abbott Lab Farmaceutiske faststofdispersionsformuleringer
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
PE20021159A1 (es) 2002-12-20
WO2002089835A3 (en) 2003-05-01
JP4101661B2 (ja) 2008-06-18
IL158306A (en) 2008-11-03
NO20034689D0 (no) 2003-10-20
US20030021840A1 (en) 2003-01-30
JO2401B1 (en) 2007-06-17
SK14572003A3 (sk) 2004-12-01
CN1547484A (zh) 2004-11-17
MXPA03009971A (es) 2004-02-12
BG108311A (bg) 2004-12-30
GT200200079A (es) 2002-12-05
MA27018A1 (fr) 2004-12-20
EP1390063B1 (en) 2004-11-17
NO20034689L (no) 2003-10-20
ATE282428T1 (de) 2004-12-15
US7014866B2 (en) 2006-03-21
CZ20033211A3 (cs) 2004-09-15
IL158306A0 (en) 2004-05-12
WO2002089835A2 (en) 2002-11-14
HUP0401238A2 (hu) 2004-12-28
JP2004527569A (ja) 2004-09-09
UA76463C2 (en) 2006-08-15
HU229938B1 (en) 2015-01-28
HRP20030873A2 (en) 2005-08-31
MY128509A (en) 2007-02-28
CN1255185C (zh) 2006-05-10
KR20040007523A (ko) 2004-01-24
CA2444116A1 (en) 2002-11-14
PL366998A1 (en) 2005-02-07
KR100554816B1 (ko) 2006-02-22
NZ528689A (en) 2005-03-24
HUP0401238A3 (en) 2012-09-28
EA006627B1 (ru) 2006-02-24
EP1390063A2 (en) 2004-02-25
ES2231717T3 (es) 2005-05-16
GEP20053466B (en) 2005-02-25
DE60201988D1 (de) 2004-12-23
PT1390063E (pt) 2005-03-31
DE60201988T2 (de) 2005-12-15
RS83503A (sr) 2006-10-27
TWI234461B (en) 2005-06-21
HRP20030873B1 (en) 2006-04-30
ECSP034827A (es) 2003-12-24
BR0209325A (pt) 2004-07-20
CA2444116C (en) 2009-01-20
EA200301166A1 (ru) 2004-04-29
PA8544501A1 (es) 2002-11-18
IS7010A (is) 2003-10-30
HK1070285A1 (en) 2005-06-17

Similar Documents

Publication Publication Date Title
AR034320A1 (es) Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo
EP1120109A3 (en) Rapidly disintegrating and fast dissolving solid dosage form
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
WO2003080023A3 (en) Fast dissolving dosage forms having reduced friability
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
DE602004009552D1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
NZ514558A (en) Viral treatment
SE9902935D0 (sv) Pharmaceutical compositions
CO5251412A1 (es) Composicion farmaceutica de mirtazapina para administracion peroral con cubierta polimerica
UY27278A1 (es) Forma de dosificación farmacéutica del mesilato de nelfinavir amorfo
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ECSP003685A (es) Formulaciones orales de liberacion controlada
SE0001916D0 (sv) Novel formulation
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
EP1698338A3 (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
AR020998A1 (es) Formulaciones de liberacion controlada de metamizol
PE20020324A1 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
AR026335A1 (es) Uso del oxido nitrico inhalable en la forma de oxido nitrico gaseoso o de un donante de oxido nitrico, en combinacion con un secuestrante de aniones superoxido para la manufactura de un medicamento y una composicion farmaceutica
PA8577801A1 (es) Polipeptido t1249 pegilado

Legal Events

Date Code Title Description
FA Abandonment or withdrawal